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SUMMARY. New direct-acting antivirals have the potential
to transform the hepatitis C (HCV) treatment landscape,
with rates of sustained viral response in excess of 90%. As
these new agents are expensive, an important question is
whether to focus on minimizing the consequences of severe
liver disease, or reducing transmission via ‘treatment as
prevention’. A back-calculation model was used to estimate
the impact of treatment of mild, moderate and compen-
sated cirrhosis on incident cases of HCV-related end-stage
liver disease/hepatocellular carcinoma (ESLD/HCC). In
addition, a dynamic model was used to determine the
impact on incidence and prevalence of chronic infection in
people who inject drugs (PWID), the main risk group in
England. Treating 3500 cirrhotics per year was predicted
to reduce ESLD/HCC incidence from 1100 (95% CrI 970–
1240) cases per year in 2015 to 630 (95% CrI 530–770)
in 2020, around half that currently expected, although
treating moderate-stage disease will also be needed to sus-
tain this reduction. Treating mild-stage PWID was required
to make a substantial impact on transmission: with 2500
treated per year, chronic prevalence/annual incidence in
PWID was reduced from 34%/4.8% in 2015 to 11%/1.4%
in 2030. There was little overlap between the two goals:
treating mild stage had virtually no impact on ESLD/HCC
within 15 years, but the long timescale of liver disease
means relatively few PWID reach cirrhosis before cessation
of injecting. Strategies focussing on treating advanced dis-
ease have the potential for dramatic reductions in severe
morbidity, but virtually no preventative impact.
Keywords: direct-acting antivirals, hepatitis C virus, liver
disease, people who inject drugs, prevention.
INTRODUCTION
Liver disease is a growing public health problem in the UK,
with a fivefold rise in liver-related mortality in the under
65s since 1970 [1]. Chronic hepatitis C (HCV) infection
contributes to a significant proportion of liver disease, with
hospital admissions in England for HCV-related end-stage
liver disease (ELSD) and hepatocellular carcinoma (HCC),
representing prevalence of severe HCV-related disease, ris-
ing from 574 in 1998 to 2652 in 2014; and reported
deaths from these indications rising fourfold from 89 in
1996 to 362 in 2014 [2]. Unless HCV treatment is scaled
up, it is likely that this trend will continue to beyond
2030, peaking at 1500 new cases of ESLD/HCC per year
[3], placing a substantial burden on health care services
and contributing to a marked reduction in lifespan.
The key risk group for HCV are people who inject drugs
(PWID) with approximately 85% of prevalent infections
due to injecting drug use in England [4]. Therefore, any
HCV intervention focusing on prevention of new infections
requires targeting PWID; that is, those with an ongoing
risk of transmission rather than those that have perma-
nently ceased injecting. Prevalence of HCV antibodies in
PWID is around 50% in England, but varies geographically
from less than 20% to over 70% [5,6]. Primary prevention
of HCV, such as needle and syringe programmes (NSPs)
and opiate substitution therapy (OST), can prevent HCV
transmission [7], but in isolation are unlikely to reduce
Abbreviations: CrI, credibility interval; DAA, direct-acting antivi-
ral; ELSD, end-stage liver disease; HCC, hepatocellular carcinoma;
HES, hospital episode statistics; IFN, interferon; ONS, Office of
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HCV transmission to very low levels [8,9]. Modelling work
has indicated that HCV treatment for PWID, combined
with traditional harm reduction interventions, could be a
cost-effective means of HCV prevention, by substantially
reducing transmission [9–11].
Historically, the number of people treated for HCV has
been low. Of approximately 160 000 adults chronically
infected in England [4], only around 5000 (3%) are treated
per year [12], with numbers being treated declining for the
first time since 2009 [2]. Recent estimates in several UK
sites have shown very low treatment rates among PWID (5–
20 per 1000 PWID annually) [6]. These low treatment rates
have been attributed to poorly tolerated interferon-based
therapies, with low efficacy in those with advanced disease
and genotype 1 infection [13], the latter accounting for
around 47% of infections in England [2]. In the past year,
however, the treatment landscape has been transformed by
new direct-acting antiviral (DAA) therapies, such as Sofos-
buvir [14], Ledipasvir and various other new agents in com-
bination undergoing approval. These new agents can be
used in easy-to-administer, all-oral regimens, which promise
shorter treatment durations, improved side effect profiles
and sustained viral response/cure rates exceeding 90% for
genotype 1 infections [15,16], and over 80% for genotypes
2 and 3 in clinical trials [17]. Early results indicate that high
SVR rates can also be achieved in the PWID population, due
to good tolerance and short treatment durations [18]. The
list price of the new therapies, however, is considerable, with
12/24 week courses of Sofosbuvir at nearly £35 000/
£70 000 [14].
NHS England has recently announced a budget of £190
million for new treatments in 2015, primarily for treating
those with cirrhosis [19]. If budgets remain at this level in
the near future, access will need to be carefully managed
to ensure maximum clinical benefit and minimum harm.
We therefore explored the potential impact of new treat-
ments on incident cases of ESLD/HCC and on HCV inci-
dence and chronic prevalence among PWID in the next
15 years, given different strategies for treatment scale-ups
in individuals with cirrhosis and pre-cirrhotic disease
stages.
MATERIALS AND METHODS
We utilized two separate models for this analysis, based on
previously published methods. The first was a back-calcula-
tion model of HCV disease progression used to predict inci-
dent cases of ESLD/HCC in England, but does not include
HCV transmission [3,20]. The second was a model of HCV
transmission among PWID, which has been used to esti-
mate the impact and cost-effectiveness of HCV treatment
scale-up strategies [10]. Both models incorporated a staged
progression of HCV disease based on categories of modified
HAI fibrosis stage [21] (Fig. 1), from infection through to
mild chronic HCV (F0-F2), moderate chronic HCV (F3-F5),
compensated cirrhosis (F6), ESLD (not including HCC),
HCC and death (either subsequent to ESLD/HCC, or natural
mortality). Individuals who are treated and achieve SVR in
mild or moderate states were assumed to experience no
further disease progression, while those that achieve SVR
in the compensated cirrhosis state may still experience dis-
ease progression, but at a much reduced rate [22]. Those
failing treatment are not treated again with the same class
of drugs. However, in the transmission model, reinfections
may be treated again with the same class of drugs.
Back-calculation model to estimate end-stage liver disease
Age-specific data from Hospital episode statistics (HES) on
ESLD and HCC, and Office of National Statistics (ONS) data
on HCC mortality were used as disease endpoints. Informa-
tion on the probabilities of progressing between disease
states was taken from published literature and combined
with the above data to derive estimates of the underlying
HCV incidence and number of individuals in each disease
state over time [3]. Estimation is implemented in a Baye-
sian framework, and inference is expressed in terms of pos-
terior distributions of the unknown quantities. These
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posterior distributions are obtained by simulation through
Markov Chain Monte Carlo using WinBUGS [23]. The
median of the posterior distribution is taken to be the point
estimate of the unknown quantity and 2.5th and 97.5th
percentiles form a 95% credibility interval (CrI), the Baye-
sian equivalent of a confidence interval. The resulting pos-
terior distributions of the disease-state structure of the
current infected population and progression probabilities
are used in subsequent modelling for estimating future
incident cases of HCV-related ESLD/HCC (Appendix 1).
Dynamic transmission model to estimate HCV chronic
prevalence and incidence among PWID
We used a dynamic, deterministic, compartmental model
of HCV transmission (Appendix 2) and disease progression
(Fig. 1) among PWID to estimate the impact of HCV treat-
ment among PWID (defined as those with an ongoing risk
of transmission) in England. New injectors enter the popu-
lation at risk of HCV infection through initiation of drug
use and exit through permanent cessation of drug use or
death. The key feature of this model is that HCV transmis-
sion is included in a dynamic way, such that the risk of
HCV transmission and reinfection among PWID is related
to the background level of transmission risk and preva-
lence of chronic infection among PWID. We make no
assumption about any behaviour change after treatment,
so that the incidence of primary infection equals that of
reinfection. The model therefore quantifies the potential
population benefits of reducing onward transmission via
treatment, while accounting for risk of reinfection.
We assumed the risk of transmission or acquisition of
HCV is independent of disease stage or duration of inject-
ing. We also assumed that the HCV epidemic among PWID
is at a stable steady-state in 2015, based on the stable
prevalence exhibited among PWID in contact with drugs
services from 2003 to 2013 [24], such that no changes in
prevalence or incidence would occur without scale-up of
existing interventions. Upon infection, 25% spontaneously
clear infection, with the remainder progressing to chronic
infection, where individuals follow the natural history of
disease progression and treatment as in Fig. 1.
The model was calibrated to estimates of the proportion
of PWID with chronic HCV in England at an estimated
34% (95% CI 31–37%), based on 45% (95% CI 41–49)
anti-HCV prevalence in this group [4] and a 25% sponta-
neous clearance rate [25]. This results in a median inci-
dence of chronic infection/reinfection among PWID of 4.8
per 100 person-years at baseline. We model a mean of
198 000 PWID in England (95% CrI 178 000–218 000)
[4] and set the inflow rate of new PWID to match the out-
flow (due to death or cessation) such that the PWID popu-
lation size is stable over time. The model was
parameterized with UK estimates of drug-related mortality
[26], average duration of injection until permanent cessa-
tion [27] and rates of disease progression used in previous
studies. To incorporate uncertainty in underlying parame-
ters, each parameter was randomly sampled from its
uncertainty range to produce 1000 parameter sets (Appen-
dix 3). Each parameter set was used, and the transmission
rate varied to calibrate the model to the sampled HCV
prevalence among PWID in 2015. For each of these 1000
parameter sets, the model was run with varying levels of
future treatments, and the median and 2.5th and 97.5th
percentile projections are shown (95% Interval). The model
was implemented in MATLAB.
Treatment scenarios
Estimates of the impact of treatment were derived by
assuming that a fixed number of individuals in different
disease states receive treatment each year. We do not con-
sider proportions currently diagnosed or increases in diag-
nosis that may be required to fulfil certain treatment
scenarios, but place a 70% cap on the maximum propor-
tion of infected individuals within a particular disease state
that may be treated within any year.
Current standard treatment was assumed to be pegylated
interferon (IFN) and ribavirin (RIB), which is assumed to
continue to be used for patients that do not receive new
DAAs. For the HCV disease burden model, age-specific SVR
rates for mild, moderate and cirrhosis stages were used
from the Trent HCV cohort study [13], which recruits from
all patients referred to participating centres in the Trent
region and consists of around 70% infected via injecting
drug use. In the HCV transmission model among PWID,
estimates of IFN/RIB SVR rates among 500 PWID in the
UK were used, which were consistent with published trials
and observational studies among noninjectors [6]. Rates
are a weighted average over genotype 1 and non-1, based
on surveillance data [12].
DAA treatments were assumed to become available from
2015, with SVR rates of 90% for mild/moderate stages,
and 80% for those with cirrhosis. These are somewhat
lower than SVR rates observed in trials [16,17] but real-
world rates are likely to be lower (as observed for IFN-
based regimens [13]) given experiences so far in early
access programmes [28]. Current treatment for cirrhotics
was assumed to be around 500 cirrhotics treated per year
with IFN-based treatment, which we compared with treat-
ing 3500 cirrhotics treated with new DAAs per year,
matching the number expected to be treated under the
new NHS budget [19]. This would represent 40% of the
estimated current number of individuals with compensated
cirrhosis in England treated in the first year, compared to
6% per year currently [2]. The population of untreated cir-
rhotics is therefore quickly exhausted, after which a maxi-
mum of 70% of the remaining untreated cirrhotic
population were assumed to be treated per year. The 70%
cap is used because it is likely that not all cirrhotics will be
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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diagnosed and ready to start treatment and is based on the
proportion anticipated to be eligible for treatment
[2,14,29]. The cap also reflects that upon developing cir-
rhosis treatment may not be initiated immediately, for
example due to late diagnosis.
We then explored the impact of treating mild-/moderate-
stage patients with new DAAs, assuming that roll-out in
these patients would start from 2016. The different scenar-
ios are summarized in Box 1.
In the transmission model base-case, half of the total
number treated were allocated as active PWID. This
assumption is intended to test the potential reductions in
incidence that could be achieved. Similarly to the cap of
70% treated annually in cirrhotics, the maximum propor-
tion of PWID treated per year in any stage was also set at
70%, as there are fewer moderate-stage PWID. Awareness
of infection in PWID is around 50% [2], so 70% assumes
there will be improvements in diagnosis, retention, referral
and treatment rates, and is probably the highest realistic
level of treatment that could be reached in this population
within the next 15 years.
A key assumption is that treatment with pegylated inter-
feron and ribavirin continues for groups that do not
receive DAAs. However, there may be reluctance among
clinicians and patients to continue the use of IFN-based
therapy in the DAA era. We therefore examined the impact
of the scenarios with scale-up in new DAAs but no further
use of IFN-based regimens.
Sensitivity analyses
We explored areas of uncertainty by varying key parame-
ters in sensitivity analyses. There is currently little evi-
dence on real-world SVR rates for new DAAs by disease
stage, so we compared scenarios with higher rates of
97.5% and 90% for all groups and lower rates of 90%,
80% and 70% in mild, moderate and cirrhosis groups,
respectively. Post-SVR progression rates are also uncertain;
we tested the impact of assuming no post-SVR progression
in those with cirrhosis, and a scenario in which post-SVR
progression of cirrhotics was half that of non-SVR (com-
pared to 10 times lower from cirrhosis to ESLD and 4 times
lower from cirrhosis to HCC at base-case [22]). Although
the clinical benefit is unlikely to be as poor as merely halv-
ing disease progression, this represents a scenario where
individuals continue to sustain liver damage, for instance
due to alcohol abuse [30]. For the PWID simulations, we
additionally explore the impact of assuming different pro-
portions of treatments allocated to PWID, such as 25%
across all disease stages or 20% cirrhosis, 40% moderate,
60% mild as compared to 50% in our base-case scenario.
RESULTS
Reductions in incident cases of ESLD/HCC
Treating 3500 cirrhotic patients with new DAAs each year
(DAAs for cirrhosis only) from 2015 was predicted to reduce
annual incidence of ESLD/HCC to 640 cases per year (95%
CrI 530–770) in 2020 compared with 1240 under current
levels of IFN-based treatment (95% CrI 1080–1440)
(Fig. 2). By 2017, the pool of untreated cirrhotics is less
than 3000 individuals, and each year 70% of this group
are treated subsequently; once treatment of cirrhotics
reaches ‘saturation’, incident cases of ESLD/HCC begin to
rise again, due to increasing numbers developing cirrhosis.
In total, 6530 (95% CrI 5570–7980) cases of ESLD/HCC
were predicted over 10 years (2016–2025) compared to
12 510 (95% CrI 10 980–14 620) under current levels of
IFN-based therapy, a reduction of 6000 (95% CrI 4910–
7080) cases due to new treatments, or nearly 50%.
We tested whether the continued use of IFN-based treat-
ment made a difference to the predicted impact that new
DAAs will have on ESLD/HCC. Without IFN-based treat-
ment for mild and moderate stages, there were predicted to
be 21 (95% CrI 15–27) more incident cases of ESLD/HCC
BOX 1: Scenarios for the scale-up of new treatments in mild-/moderate-stage patients. all acenarios assume 3500
cirrhosis patients, up to a maximum of 70% of the remaining untreated cirrhotic population, are treated each year
in England.
 DAAs for cirrhosis only: Three thousand five hundred persons with cirrhosis, per year, up to 70% of the untreated
cirrhotic population. About 50% of these are allocated as active PWID (up to a maximum of 70%). Maintain standard
treatment at current rates for all other disease states: 2000 moderate and 2000 mild per year total, with 50% of
these allocated as PWID (1000 moderate and 1000 mild).
 DAAs for cirrhosis and moderate: as in (1) plus 5000 persons with moderate-stage infection receive new treatments
per year from 2016. About 50% of these are allocated as active PWID in the transmission model (2500, up to a
maximum of 70%).
 DAAs all stages: as in (2), plus 5000 persons with mild-stage infection receive new treatments per year from 2016.
About 50% of these are allocated as active PWID (2500, up to a maximum of 70%).
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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in 2020 (3.3% higher) and 59 (95% CrI 44–76) more in
2025 (7.8% higher). Further details are given in supple-
mentary materials.
Treating 5000 moderates per year with new DAAs from
2016, in addition to cirrhotics (DAAs for cirrhosis and mod-
erate), largely averts the predicted rebound in incident
cases of ESLD/HCC, with incident cases not exceeding 600
per year and slowly beginning to decline from a maximum
of 600 (95% CrI 480–770) in 2025 (Fig. 2). The total
number of additional cases prevented over 10 years com-
pared to treating cirrhotics only is 660 (95% CrI 500–
850). The further scale-up of DAAs for mild patients (DAAs
all stages) had limited additional impact: virtually no differ-
ence was observed by 2020 compared to DAAs for cirrhosis
and moderate, and even at 2025 the reduction in annual
incident cases was only 16 cases (95% CrI 12–20). This
reflects the long lead-time before severe disease develops in
those at mild stage.
Reductions in incidence and prevalence of chronic HCV
among PWID
At 2015, the model was calibrated such that chronic HCV
prevalence among PWID was stable at a median of 34%
(95% CrI 29–37%) with an annual incidence rate of 4.8%
(95% CrI 3.6–8.1%). In this equilibrium state, the model
predicts 79%, 16%, 5% in the mild, moderate, cirrhosis or
later stages, respectively.
Estimated prevalence and incidence of chronic infection
among PWID are shown in Fig. 3. Treating cirrhosis alone
with DAAs (DAAs for cirrhosis only) had negligible impact
on predicted incidence and prevalence of chronic infection
among PWID due to the rarity of advanced disease in this
population. Only 7474 PWID (95% CrI 3834–11 782)
were treated over the 15 years, and prevalence was
reduced to 32% (95% CrI 27–35%) and incidence to 4.4%
(95% CrI 3.6–7.9%) by 2030. With standard IFN/RBV
treatment in mild and moderate stages (1000 per year in
each) alongside treatment of cirrhotics with DAAs, preva-
lence was reduced to 25% (95% CrI 21–29%) and inci-
dence to 3.5% (95% CrI 2.6–6.6%) by 2030. Treating
2500 moderate-stage patients per year with DAAs (DAAs
for cirrhosis and moderate) had some impact, with chronic
prevalence estimated at 24% (95% CrI 20–28%) and inci-
dence at 2.8%(95% CrI 2.1–5.7%) in 2030. However, by
2021, there are fewer PWID in the moderate stage than
available treatments; in other words, as there are only
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16% of PWID in the moderate stage, the pool of people to
treat at this stage runs out. The additional scale-up of
DAAs to mild stage, however, with 2500 treated per year
(DAAs for all stages) reduced chronic prevalence to 11%
(95% CrI 6–15%) and incidence to 1.4% (95% CrI 0.7–
3.5%) by 2030. In this scenario, nearly two-thirds of the
mild stage were treated, with a total of 68 179 PWID
(95% CrI 61 236–75 210) treated over 15 years. It should
be noted that the incidence rate of chronic infection is
approximately 25% lower than the incidence rate of HCV
exposure, due to spontaneous clearance [25].
Sensitivity analyses
With better SVR rates, incident cases of ESLD/HCC are
reduced by approximately the same degree in all scenarios,
by around 60–80 cases per year (13% reduction vs base-
case in 2020) under 90% SVR rates for all disease stages
and by 120–140 cases under 97.5% SVR rates (90% for
mild/moderate and 80% for cirrhosis in the base-case). With
90% SVR, marginal differences (<2%) are found for HCV
prevalence among PWID in all scenarios. However, a 97.5%
SVR results in 22% lower HCV prevalence among PWID in
2030 for the DAA for all scenarios compared to base-case.
With worse SVR rates for moderate and cirrhosis stage
(80% and 70%, compared to 90% and 80% in base-case,
respectively), incident ESLD/HCC was predicted to be
around 80 cases higher (15% increase vs base-case in
2020) for the DAAs for cirrhosis only scenario, with negligi-
ble difference (<1%) in HCV chronic prevalence among
PWID in 2030 compared to base-case. Cases of ESLD/HCC
are around 130 higher for scenarios that treat pre-cirrhotic
stages, as the additional benefits of treating moderate stage
are less. HCV chronic prevalence among PWID in 2030 is
5–10% higher compared to base-case for pre-cirrhotic
scale-up scenarios.
Changes to post-SVR progression rates had a greater
impact on incident cases of ESLD/HCC, although the varia-
tion in assumed values was fairly extreme. For DAAs for cir-
rhosis only, there were predicted to be up to 320 additional
cases of ESLD/HCC in 2020 (51% higher than base-case) if
progression is only halved post-SVR compared to the base-
line rates, and up to 160 fewer cases if progression is halted
entirely (25% lower than base-case), although the difference
increased over time. For scenarios that treat precirrhotic
stages, changes in post-SVR progression rates have less
impact, as fewer patients progress to cirrhosis. No difference
was seen in impact on HCV prevalence among PWID with
variations in post-SVR progression rates due to the very
small number of PWID in later disease stages. Plots of pre-
dicted ESLD/HCC and prevalence/incidence of chronic HCV
infection among PWID under the different sensitivity analy-
ses are available in supplementary materials.
With fewer treatments allocated to PWID (25% com-
pared to 50% at base-case) there was less impact on HCV
chronic prevalence among PWID, at 2030 a relative 13%
higher in the DAA for cirrhosis and moderates scenario, and
74% higher in the DAA for all stages scenario (mean 19%
chronic prevalence in 2030, 11% in base-case). If 60%,
40%, 20% of mild, moderate and cirrhotic treatments,
respectively, are allocated to PWID (50% at base-case),
then more impact is achieved in the DAA for all stages sce-
nario, with HCV chronic prevalence 25% lower in 2025
(8% chronic prevalence in 2030, 11% in base-case); mar-
ginal differences (<2%) are seen for other scenarios.
DISCUSSION
Main findings
These analyses suggest that targeting new DAAs to people
with cirrhosis will result in a rapid reduction in incident
cases of ESLD/HCC within 2–3 years, to around half of
that currently predicted in 2020, but with little impact on
HCV incidence among PWID. Due to lower SVR rates in
those with cirrhosis, continued post-SVR progression (albeit
at low rates) and rising numbers developing cirrhosis,
treating those at moderate disease stage is also required to
prevent a rebound in incident cases of ESLD/HCC. The total
number of individuals either living with cirrhosis or having
achieved SVR while cirrhotic was predicted to steadily
increase, rising from 9330 (95% CrI 7090–12 020) in
2015 to 16 760 (95% CrI 13 730–21 000) in 2025, with
an increasing number of moderate stage developing cir-
rhosis each year. Therefore, a rebound in ESLD/HCC (fol-
lowing ‘saturation’ of cirrhotic treatment) is to be
expected unless individuals can be prevented from reach-
ing cirrhosis in the first place. Re-treatment may mitigate
the increased risk of treatment failure in patients with cir-
rhosis to some extent, but there is still the risk of contin-
ued liver disease. The extent to which the risk of severe
liver disease persists post-SVR is not yet fully understood,
although some studies suggest that fibrosis can be
reversed [31]. Sensitivity analyses indicated that even
with SVR rates of virtually 100% (which could represent
multiple rounds of treatment), without treating those at
moderate-stage ESLD/HCC will continue to rise beyond
2020 unless there is also no risk of post-SVR progression.
Clearly, there are potential risks to delaying treatment
until patients develop cirrhosis.
New DAAs also offer the potential to reduce incidence
and chronic prevalence in the PWID population by two-
thirds within 15 years. However, this requires treatment of
those at mild stage, as the majority of PWID do not pro-
gress beyond mild stage during their injecting career.
Treating PWID at moderate stage showed a 10% reduction
in chronic prevalence, from 34% to 24%, but as a rela-
tively small proportion of active PWID progress beyond
mild stage, there are not enough moderate-stage PWID to
treat to make a substantial impact on transmission. This is
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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in contrast to predicted incident cases of ESLD/HCC, which
was only affected by treating moderate and cirrhotic stage
disease within the time frame examined here.
Strengths and limitations
By testing the impact of the same treatment scenarios
within both a burden projection model and a dynamic
transmission model, the impact on different aspects of
harm reduction can be compared directly. This study pro-
vides the first population-level assessment of the potential
impact of new DAAs in England and the forthcoming NHS
England treatment programme, quantified with total num-
bers treated in the infected population and in PWID. The
proportion of treatments that are assumed to be ‘allocated’
to PWID is high, with the aim of assessing the potential
impact rather than what might be feasible. The proportion
of PWID treated will not affect the conclusion that the two
reduction targets of transmission and severe disease have
little overlap, but clearly if a lower proportion of those
treated are active PWID, there will be a smaller reduction
in transmission.
The disease burden model combines observed data on
ESLD/HCC and HCC mortality from HES and the ONS, pro-
gression rates from the literature and estimates of overall
population prevalence. The model should therefore provide
an accurate picture of the current and future disease bur-
den that England faces, and the potential impact of treat-
ment. The main limitations are that there are no recent
estimates of population prevalence; observed HES data may
underreport HCV-related ESLD/HCC to some extent; and
the assumed model structure necessarily makes assump-
tions regarding relative risks of age-specific progression
and the distribution of age at infection.
The transmission model also has areas of uncertainty,
primarily surrounding estimation of size of PWID popula-
tion, natural history of injecting [32] and number of treat-
ments allocated to PWID. For example, estimates of the
PWID population range from less than 100 000 [33] to
nearly 200 000 [34]. Average prevalence of HCV in PWID
in England is reasonably well established [2,4] but subject
to substantial local variation [5,6], which greatly affects
the impact of treatment as prevention [11]; further, treat-
ment rates in PWID vary substantially between settings
[6]. Length of injecting career is highly uncertain, with
very limited data that can provide reliable estimates [27].
We assume an average duration of 11 years, which leads
to few PWID reaching cirrhosis before cessation. Disease
progression in PWID has not been well studied; here, we
have taken published estimates of disease progression used
in previous modelling, which are consistent with those esti-
mated from the burden model for the typical age range of
this population. In any case, substantially higher rates in
PWID would be required to alter the finding that cirrhosis
is generally rare in this population.
We assume the risk of transmission or acquisition of HCV
is independent of disease stage or duration of injecting. Sev-
eral studies have noted that HCV prevalence rises quickly
the first few years of injecting and then stabilizes [35], but
heterogeneity in risk behaviour may also lead to rapid infec-
tion in high-risk individuals, with infections occurring more
slowly in lower-risk groups subsequently. One UK-based
modelling study [36] indicated strong population hetero-
geneity in risk behaviour, but also an elevated risk of HCV
acquisition within the first year of injecting. By contrast, a
recent study from Australia [32] showed that while the risk
of injecting cessation increases over time, marginal differ-
ences were seen in risk behaviours among those who
remain injecting. If injecting risk is heightened within the
first year of injecting and HCV treatment reaches PWID
later in their career, this would reduce the population-level
impact projected here. Nevertheless, our findings support
previous modelling work indicating that the existing level of
HCV treatment in the UK is unlikely to result in measurable
impact among PWID, but that scale-up could dramatically
reduce chronic prevalence among PWID [6,11,37].
Key uncertainties include the actual SVR rates of new
treatments in practice, which are likely to be worse than
those observed in clinical trials, and the lack of long-term
outcome data in those that achieve SVR where cirrhosis
has already developed. Crucially, it is also uncertain to
what extent SVR rates are reduced in patients with cirrhosis
compared to pre-cirrhotic disease stages. Finally, it is not
known to what extent treating DAA-failures with other reg-
imens will be viable, with issues such as cross-class drug
resistance still being investigated. Our base-case assumption
was for no re-treatment, but we sought to consider alterna-
tives by testing assumptions of higher overall SVR rates,
and other uncertainties listed above, in sensitivity analyses.
Implications
These analyses show that the major concerns relating to
HCV, rising severe liver disease and ongoing transmission,
can be addressed with the advent of new DAAs. Treating
those with cirrhosis fulfils the short-term goal of reducing
ELSD/HCC, although treatment of moderate stage is needed
to prevent a subsequent rebound. Treatment of mild-stage,
active PWID is required to substantially reduce HCV trans-
mission, which must be addressed if the long-term goal of
elimination of HCV as a significant public health concern
is to be achieved.
Progress towards reducing ESLD/HCC should be imme-
diately observable via HES data and liver-related mortal-
ity, although reductions in transmission will be harder to
detect. Changes in incidence cannot easily be observed
directly, and falling chronic prevalence will occur slowly
and also be difficult to monitor accurately, with current
monitoring via anonymous surveys testing for antibodies
[38]. A trial of ‘treatment as prevention’ is therefore
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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desirable to demonstrate an intervention effect and to
establish what data collection systems are required to
monitor progress. Collecting national treatment uptake
and outcomes data are crucial for monitoring progress
and predicting likely impact. Currently no national data
collection for HCV treatment is undertaken and numbers
are only estimated indirectly [2], with real-world SVR
rates only available from localized cohort studies. Fortu-
nately, monitoring is set to improve with the roll-out of
new therapies.
With a budget of £190 million for new DAAs announced
in June 2015 and current focus on treating those with cir-
rhosis [19], only the short-term goal of reducing ESLD/HCC
over the next 5 years can be achieved. Clearing the current
pool of those diagnosed with cirrhosis could be achieved
within 2–3 years at the treatment levels here. With recent
NICE approval for use in all stages of genotype 1 infection,
treatment of pre-cirrhotic stages should follow shortly.
Reductions in HCV transmission, however, will require a
change in strategy to treat substantial numbers of active
PWID, most of whom will have relatively mild disease.
The key issue for any managed, targeted treatment strat-
egy is whether individuals in the appropriate groups can be
identified and treated in a timely way. One potential strategy
would be to monitor patients using fibrosis scans and only
initiate treatment when a defined high-risk fibrosis stage is
reached [39]. However, limitations of current technology
mean that there is a chance that some high-risk individuals
may be missed. In addition, marginalized groups may
become disengaged from long-term monitoring (or ‘watchful
waiting’) programmes and miss out on future treatment
opportunities, therefore widening health inequalities. Like-
wise, it is uncertain whether there is any place for ongoing
use of standard treatments as a first-line approach from prac-
tical, ethical or patient/clinician acceptability standpoints.
The scenarios here also require a certain quota of peo-
ple to be treated each year. While it is likely that the
majority of those with cirrhosis will be diagnosed, treat-
ing 70% of the remaining pool each year may be difficult
to achieve in practice. Late diagnosis of cirrhosis will
result in continued high levels of severe liver disease.
Treating 5000 mild and 5000 moderate per year would
be a relatively small proportion of the current infected
population, but as the pool of diagnosed individuals
diminishes, sustaining high numbers in treatment may be
difficult unless testing, diagnosis and patient engagement
improve. Diagnosing and treating sufficient numbers of
PWID may be difficult, although recent advancements in
case-finding through dried blood spot testing and volun-
tary opt-out in prison are likely to increase diagnosis
rates in this population [40,41]. New methods of treat-
ment delivery, such as community settings, may need to
be expanded to achieve the treatment levels among PWID
that are modelled here.
CONCLUSIONS
With the arrival of new DAA treatments, the outlook is
extremely good for HCV-infected patients, with the risk
of severe HCV-related liver disease being markedly
reduced. However, SVR rates in cirrhotic patients may be
lower than pre-cirrhotic patients, treatment of cirrhosis
may not prevent further disease progression in all indi-
viduals, and treatment of cirrhotic patients will have lit-
tle benefit on preventing new HCV infections. Therefore,
focussing solely on cirrhotics is not a tenable long-term
strategy if continued reductions in incident cases of
ESLD/HCC and reductions in transmission are to be
achieved. NHS England is currently rolling out new
DAAs to those with cirrhosis, but treatment of other
groups will need to follow quickly. Providing equitable
access to expensive treatments will require a difficult bal-
ance between increasing the budget for treatment and
negotiating lower prices.
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APPENDIX 1. Back-calculation
approach
Back-calculation incorporates knowl-
edge of progression probabilities
taken from the literature (prior distri-
butions) which are combined with
the observed data to produce poste-
rior distributions for the quantities of
interest. The approach is based on
the observation that in a disease
with long incubation period, there is
a long delay between infection and
the development of the disease end-
point [42]. Let t0 < t1. . . < tN parti-
tion time between t0 and tN into
intervals of equal length. Then, in
discrete time, this idea can be
analytically expressed through the
relation
li ¼
Xi
j¼0hjfji (1)
linking the three components of the
back-calculation: µi, the expected
number of occurrences of the end-
point of interest in the time interval
[ti, ti+1]; hj the expected number of
new infections during [tj, tj+1]; and
fji, the probability that infections in
the interval [tj, tj+1] experience the
endpoint in [ti, ti+1] for i = 1 . . .
N  1. So, given data on the end-
point over time and knowledge of the
distribution of the time between infec-
tion and endpoint, it is possible to
reconstruct the temporal pattern of
the new infections. Estimation typi-
cally proceeds by assuming that the
underlying, unobserved, infection
process is Poisson; that is the number
of new infections in any interval [tj,
tj+1] has a Poisson distribution with
mean hj. From this, through (1), the
number of new cases of the endpoint
in the interval [ti, ti+1] is Poisson dis-
tributed with mean µi. The distribu-
tional assumption allows the
derivation of the likelihood of the
observed data over the period
between t0 and tN as a product of
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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Annual probability (95% CrI)
Prior Posterior
Acute to chronic infection
0.7376 (0.6984, 0.7730) 0.7376 (0.6984, 0.7730)
Chronic HCV to moderate chronic HCV
0–9 0.0204 (0.0117, 0.0331) 0.0161 (0.0085, 0.0278)
1–10 0.0197 (0.0116, 0.0306)
20–29 0.0158 (0.0092, 0.0238)
30–39 0.0089 (0.0029, 0.0218) 0.0115 (0.0045, 0.0204)
40–49 0.0156 (0.0056, 0.0338) 0.0425 (0.0249, 0.0637)
50–59 0.0534 (0.0345, 0.0782) 0.0523 (0.0337, 0.0776)
60–69 0.0593 (0.0379, 0.0843)
70–79 0.0667 (0.0459, 0.0921)
80+ 0.0546 (0.0354, 0.0787)
Moderate chronic HCV to cirrhosis
0–9 0.0075 (0.0010, 0.0258) 0.0001 (0.0000, 0.0004)
1–10 0.0023 (0.0013, 0.0047)
20–29 0.0074 (0.0048, 0.0134)
30–39 0.0036 (0.0001, 0.0219) 0.0168 (0.0109, 0.0267)
40–49 0.0065 (0.0004, 0.0271) 0.0261 (0.0189, 0.0392)
50–59 0.0282 (0.0062, 0.0786) 0.0142 (0.0076, 0.0264)
60–69 0.0293 (0.0204, 0.0398)
70–79 0.0563 (0.0360, 0.0831)
80+ 0.1355 (0.0919, 0.1994)
Cirrhosis to hepatocellular carcinoma
0–29 0.0079 (0.0040, 0.0159) 0.0068 (0.0043, 0.0093)
30–39 0.0130 (0.0075, 0.0219) 0.0113 (0.0080, 0.0148)
40–49 0.0212 (0.0142, 0.0311) 0.0186 (0.0145, 0.0233)
50–59 0.0347 (0.0249, 0.0475) 0.0307 (0.0247, 0.0385)
60–69 0.0565 (0.0381, 0.0792) 0.0513 (0.0402, 0.0671)
70+ 0.0913 (0.0561, 0.1469) 0.0844 (0.0639, 0.1211)
Cirrhosis to decompensated cirrhosis (end-stage liver disease)
0–29 0.0651 (0.0139, 0.2610) 0.1490 (0.0804, 0.2230)
30–39 0.0641 (0.0219, 0.1750) 0.1286 (0.0801, 0.1793)
40–49 0.0648 (0.0324, 0.1186) 0.1123 (0.0800, 0.1465)
50–59 0.0649 (0.0403, 0.0951) 0.0974 (0.0763, 0.1254)
60–69 0.0635 (0.0336, 0.1186) 0.0851 (0.0681, 0.1111)
70+ 0.0630 (0.0229, 0.1675) 0.0748 (0.0558, 0.1010)
Decompensated cirrhosis to hepatocellular carcinoma
0–29 0.0155 (0.0074, 0.0328) 0.0114 (0.0034, 0.0222)
30–39 0.0252 (0.0137, 0.0440) 0.0186 (0.0065, 0.0346)
40–49 0.0410 (0.0248, 0.0644) 0.0305 (0.0120, 0.0548)
50–59 0.0665 (0.0416, 0.1026) 0.0502 (0.0228, 0.0884)
60–69 0.1091 (0.0646, 0.1751) 0.0835 (0.0419, 0.1427)
70+ 0.1762 (0.0945, 0.3251) 0.1371 (0.0730, 0.2300)
Decompensated cirrhosis to liver-related mortality (not hepatocellular carcinoma)
0.1857 (0.1289, 0.2556) 0.2930 (0.2288, 0.3576)
Hepatocellular carcinoma to death specific to hepatocellular carcinoma
0.6032 (0.5323, 0.6774) 0.6026 (0.5510, 0.6541)
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Poisson variables whose means are
functions of the unknown hj. By suit-
ably expressing the hj in terms of
parameters h, that is hj = hj(h), the
maximization of the likelihood pro-
vides estimates of the parameters and
of the number of new infections over
time.
A Bayesian approach to this esti-
mation involves the specification of a
prior distribution on h. This prior can
then be combined with the likelihood
to produce a posterior distribution
reflecting both a priori knowledge
and the information from the
observed data. The combination of
these two information components is
carried out using Bayes’ theorem,
according to which
pðhjdataÞ / pðhÞ  pðdatajhÞ (2)
where p(h) is the prior information
on h, p(data|h) is the likelihood of the
data and p(h|data) represents the pos-
terior distribution of h after observing
the data. Summaries of the posterior
distributions, specifically medians, are
taken as point estimates, and the
2.5th and 97.5th percentiles forming
the credible interval (CrI), the Baye-
sian equivalent of a 95% confidence
interval.
In this article, endpoint data are
based on hospital admissions for
HCV-related end-stage liver disease
(ESLD) and hepatocellular carcinoma
(HCC), which are obtained from
Hospital Episode Statistics (HES) data;
and HCV-related HCC deaths from
the ONS. Given that ESLD and HCC
are serious conditions requiring
urgent medical attention, the HES
data are taken to be a measure of
population-level prevalence of these
conditions. HCV infection status for
HCC deaths is taken to be under-
reported and corrected for using the
method described by Sweeting et al.
[20]. The observed data are in the
form of aggregate counts of number
occupying these disease states (or the
incident occurrence, for deaths) each
year, according to 10-year age
groups. Summaries of observed hospi-
tal admissions for end-stage liver dis-
ease and hepatocellular carcinoma,
and mortality, are available from pre-
vious Public Health England reports
(2).
The resulting output from the
model therefore includes posterior dis-
tributions of the progression rates
and the number of individuals within
each disease state over time. This
output thus forms the basis of future
projections, with the numbers in each
disease state at time t + 1 derived
from the infected population structure
at the current time, t and rates of
progression to subsequent stages.
Age-specific prior and posterior distri-
butions for the progression probabili-
ties are shown below.
APPENDIX 2. Model schematic of
infection and treatment in the population of people who inject drugs (PWID).
Susceptible PWID
Spontaneously
cleared 
PWID
Chronically infected 
(see schematic for 
disease progression)
SVR (allow progression from 
compensated cirrhosis SVR stage)
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APPENDIX 3. Parameters for HCV transmission among PWID
Mean value Distribution Reference
Disease state transition probabilities per year (probabilities converted to instantaneous rates)
Mild HCV to moderate HCV 0.025 Beta (a = 38.0859, b = 1485.3516) [43]
Moderate HCV to compensated
cirrhosis
0.037 Beta (a = 26.905, b = 700.2582) [43]
Compensated cirrhosis to ESLD 0.039 Beta (a = 14.6168, b = 360.1732) [43]
Compensated cirrhosis to ESLD
SVR, relative risk of non-SVR
7% Lognormal (95% CI 0.03, 0.20) [44,45]
Compensated cirrhosis/ESLD to
HCC
0.014 Beta (a = 1.9326, b = 136.1074) [43]
Compensated cirrhosis to HCC
SVR, relative risk of non-SVR
23% Lognormal (95%CI 0.16, 0.35) [45]
ESLD to death 0.13 Beta (a = 147.03, b = 983.97) [43]
HCC to death 0.43 Beta (a = 117.1033, b = 155.23) [43]
Epidemiological parameters
Number of PWID in England 198 000 Normal (95%CI 178 000–218 000) [4]
HCV chronic prevalence among
PWID
34% Normal (95%CI 31–37%) [4]
Average injecting duration until
permanent cessation (years)
11 Uniform (6,16) [27]
Average PWID excess death rate
per year
0.01 Poisson [26]
Proportion genotypes 1 and 4 50% [46]
Proportion genotypes 2 and 3 50% [46]
PWID SVR genotypes 1 and 4 with
IFN/RIB
45% Uniform (33–57%) [6]
PWID SVR genotypes 2 and 3 with
IFN/RIB
61% Uniform (47–76%) [6]
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